Treatment With Full-spectrum Cannabis Extract of Refractory Epilepsy Associated With Tuberous Sclerosis Complex (TSC)

Key facts

Sponsor

Oils4Cure

Principal Investigator

Gil Nagel, Antonio Gil Nagel, Antonio, Doctor, P.T

Intervention

YCJ-01 Full Spectrum cannbis Extract(drug)

Enrollment

84 enrolled

Eligibility

2-65 years · All sexes

Timeline

2024 – 2026

Study locations (1)

• Hospital Ruber Internacional, Madrid, Spain

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Tuberous sclerosis complex

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONNANCT06879665
  TANDem-2: Closing the Gap to Interventions for TAND
  Vrije Universiteit Brussel
• RECRUITINGNANCT06160310
  Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
  David M. Ritter
• RECRUITINGPHASE2NCT05104983
  Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
  Darcy Krueger
• RECRUITINGNANCT06764602
  Observational, Retrospective, Multicenter, Nonprofit Study on the Prevalence of Renal Involvement in Pediatric Patients With Tuberous Sclerosis
  IRCCS Azienda Ospedaliero-Universitaria di Bologna
• ACTIVE NOT RECRUITINGNANCT04198181
  The Effectiveness and Safety of Resective Epilepsy Surgery for TRE
  Beijing Children's Hospital
• ACTIVE NOT RECRUITINGPHASE3NCT02962414
  Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
  Novartis Pharmaceuticals
• RECRUITINGNANCT00001465
  Study of the Disease Process of Lymphangioleiomyomatosis
  National Heart, Lung, and Blood Institute (NHLBI)

See all trials for Tuberous sclerosis complex →